Genmab Signs Agreement with DSM Biologics to Produce Clinical and Commercial Supply of HuMax-CD4
03-Jun-2004
Copenhagen, Denmark: Genmab A/S announced it has signed an agreement with DSM Biologics to produce a commercial supply of HuMax-CD4, Genmab's antibody for the treatment of T-cell lymphoma. DSM will manufacture c-GMP batches of HuMax-CD4 for clinical trials and subsequent commercial supply. The material will be produced in DSM's facility in Groningen, the Netherlands.
Most read news
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/bionity/images/newsletter.png)
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.